RxDoctor Payments Data

Charity Johnson, DO

Family Medicine · Fort Gibson, OKNPI 1730522129

Payments from drug & device makers

$6,448in general payments, 2019–2025

Across 414 payments — averaging $15.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • AstraZeneca$788
  • Lilly USA, LLC$580
  • Amgen$337
  • GSK$290
  • plus $2K from 39 others

What the payments were for

  • Food & beverage$6,38599%
  • Education$631%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,448 in reported general payments places this provider in the 85th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$51,690
Medicare patients
271
Services billed
719

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide49$54,220
JardianceEmpagliflozin43$41,287
OzempicSemaglutide36$39,070
EliquisApixaban54$31,776
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$30,745
Tresiba Flextouch U-200Insulin Degludec12$11,465
Emgality PenGalcanezumab-Gnlm13$10,197
XareltoRivaroxaban35$9,648
Breo ElliptaFluticasone/Vilanterol12$8,185
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$5,826
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,136
Venlafaxine Hcl ErVenlafaxine Hcl25$4,617
Albuterol Sulfate HfaAlbuterol Sulfate60$2,112
Omeprazole137$1,941
Atorvastatin Calcium189$1,682

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$580$54,22049 claims
Boehringer IngelheimJardiance, Stiolto Respimat$199$47,11355 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$290$44,06662 claims
Novo NordiskOzempic$1,203$39,07036 claims
PfizerEliquis$238$31,77654 claims
Johnson & JohnsonXarelto$16$9,64835 claims
AbbVieSynthroid$1,049$56814 claims
Almatica Pharma LLCSertraline Hcl$28$45067 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Fort Gibson

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →